Brigham & Womens Hospital Inc.

Brigham & Womens Hospital Inc., doing business as Department Of Faulkner Pathology, is a subsidiary of Partners Healthcare System Incorporated (Mass General Brigham) based in Boston, Massachusetts. The hospital operates as a prime recipient on federal grants and a prime contractor on federal service and clinical delivery contracts, competing full-and-open across federal healthcare and research funding streams with no SBA set-aside designations.

The hospital's federal footprint centers on biomedical research and clinical services delivery. On the research side, Brigham & Womens delivers investigator-initiated life science and health services research across NIH institutes—particularly the National Heart Lung and Blood Institute (576 awards, $145.2 million), the National Institute on Aging, the National Cancer Institute, and the National Institute of Allergy and Infectious Diseases. Recent representative grant work includes $3.69 million from the National Institute on Aging for investigating transfer RNA-derived fragments in tau pathology and Alzheimer's disease; $3.08 million from NIAID for studying T Helper 2 memory cell populations in chronic type 2 inflammation; and $1.7 million from NHLBI for developing and validating novel therapeutic approaches to atherosclerosis and metabolic dysfunction-associated steatohepatitis using small activating RNA delivered via lipid nanoparticles. Across SCI-reportable federal service contracts (FY2022–FY2023), the hospital invoiced $9.3 million with a median government-paid rate of $152.45 per hour, ranging from $46.33/hr (10th percentile) to $2,973.59/hr (90th percentile), serving as a prime on 48 contracts and performing zero sub-hours share on its contracts.

On the clinical services side, the hospital holds a single-award indefinite delivery contract with Veterans Integrated Service Network 1 (VA) ceiling-valued at $5 million for lung transplant services. Under this vehicle, VISN 1 issued a $3.34 million delivery order on July 1, 2026, for lung transplant services in Boston through June 30, 2027, and an additional $2.17 million delivery order on January 1, 2026, through June 30, 2026. Additional VA task orders include a $645 thousand BPA call for pathology and laboratory services (AP, CP, CYTO and surgical consults, semen analysis, autopsy services) and smaller purchase orders from NIH institutes (National Institute on Aging, National Institute of Environmental Health Sciences, National Institute of Dental and Craniofacial Research) for clinical laboratory services related to biospecimen processing, DNA sequencing, and bioinformatics research support.

Federal customer concentration is heavily weighted toward HHS/NIH agencies, which account for 55% of awards by count with a combined potential value centered on NHLBI ($145.2 million across 576 awards). Veterans Health Administration (VISN 1) represents the second-largest dollar customer ($68 million across 111 awards), anchored by the lung transplant services IDIQ. The hospital acts as the administrative and financial overhead for numerous NIH-funded cooperative agreements and multicenter consortium projects, where it serves as a coordinating center, enrolling site, or supporting site for clinical trials and research networks. Teaming relationships are extensive: across the grant sub-award portfolio, the hospital partners with Harvard-affiliated institutions (Massachusetts General Hospital, Harvard Medical School, Harvard T.H. Chan School of Public Health), Boston-area medical centers (Children's Hospital Boston, Boston Children's Hospital, Beth Israel Deaconess Medical Center), and national research institutions (Johns Hopkins University, Columbia University, Stanford University, University of Michigan, University of Washington) as both prime recipients and sub-recipients on NIH grants.

Recent grant awards due for completion in the next 24 months carry combined potential value of $23.2 million, including projects on circadian rhythm disruption, precision medicine for cancer and cardiovascular disease, and clinical intervention development. The hospital's recent activity shows 513 awards in 2024 and 358 in 2025, compared to 283 and 297 respectively in 2022 and 2023, indicating sustained research funding momentum. Across the full prime and sub-award footprint (4,424 total awards), the hospital has generated $9.69 billion in obligated dollars against $538.7 million in combined potential value, reflecting the maturity and scale of its federal research and clinical services portfolio.